AIM: To assess if cardiovascular risk (CVR) charts are able to identify the increased risk caused by androgen deprivation therapy (ADT) in patients with prostate cancer (PCa). DESIGN: Retrospective cohort study. LOCATION: Urban and rural health centres in the province of Ourense. PARTICIPANTS: Patients diagnosed with PCa who had been prescribed treatment for ADT between 2007 and 2008. MAIN MEASURES: Age, residence (rural/urban), staging (Gleason), diagnostic procedure and, at the beginning and end of follow-up, lipid profile, blood pressure, diagnosis of diabetes mellitus, smoking, use of antihypertensive and lipid-lowering drugs, and Framingham calibrated and ATP III indexes, were determined. Cardiovascular events were recorded during the follow-up. Each patient was his own control. Increasing age was not used in the calculation of the scores at the end of the follow up period. The scores were compared using the t-test for paired samples (SPSS 15.0). RESULTS: A total of 209 cases were included. The mean (SD) age was 73.8 (8.0) years, with 64.6% of urban cases. The scores at baseline and at 12 months of follow-up were: Framingham 9.0 (4.6) and 9.2 (4.8) (P=0.5), ATP III 14.2 (1.7) and 14.2 (1.7) (P=0.9). CONCLUSION: CVR charts do not assess the increased risk associated with androgen deprivation therapy in prostate cancer.
AIM: To assess if cardiovascular risk (CVR) charts are able to identify the increased risk caused by androgen deprivation therapy (ADT) in patients with prostate cancer (PCa). DESIGN: Retrospective cohort study. LOCATION: Urban and rural health centres in the province of Ourense. PARTICIPANTS: Patients diagnosed with PCa who had been prescribed treatment for ADT between 2007 and 2008. MAIN MEASURES: Age, residence (rural/urban), staging (Gleason), diagnostic procedure and, at the beginning and end of follow-up, lipid profile, blood pressure, diagnosis of diabetes mellitus, smoking, use of antihypertensive and lipid-lowering drugs, and Framingham calibrated and ATP III indexes, were determined. Cardiovascular events were recorded during the follow-up. Each patient was his own control. Increasing age was not used in the calculation of the scores at the end of the follow up period. The scores were compared using the t-test for paired samples (SPSS 15.0). RESULTS: A total of 209 cases were included. The mean (SD) age was 73.8 (8.0) years, with 64.6% of urban cases. The scores at baseline and at 12 months of follow-up were: Framingham 9.0 (4.6) and 9.2 (4.8) (P=0.5), ATP III 14.2 (1.7) and 14.2 (1.7) (P=0.9). CONCLUSION: CVR charts do not assess the increased risk associated with androgen deprivation therapy in prostate cancer.
Authors: Jaume Marrugat; Pascual Solanas; Ralph D'Agostino; Lisa Sullivan; José Ordovas; Ferran Cordón; Rafael Ramos; Joan Sala; Rafael Masià; Izabella Rohlfs; Roberto Elosua; William B Kannel Journal: Rev Esp Cardiol Date: 2003-03 Impact factor: 4.753
Authors: Majon Muller; Diederick E Grobbee; Isolde den Tonkelaar; Steven W J Lamberts; Yvonne T van der Schouw Journal: J Clin Endocrinol Metab Date: 2005-02-01 Impact factor: 5.958
Authors: A Gondos; F Bray; D H Brewster; J W W Coebergh; T Hakulinen; M L G Janssen-Heijnen; J Kurtinaitis; H Brenner Journal: Eur J Cancer Date: 2008-04-30 Impact factor: 9.162
Authors: Henry K Tsai; Anthony V D'Amico; Natalia Sadetsky; Ming-Hui Chen; Peter R Carroll Journal: J Natl Cancer Inst Date: 2007-10-09 Impact factor: 13.506
Authors: Anthony V D'Amico; James W Denham; Juanita Crook; Ming-Hui Chen; Samuel Z Goldhaber; David S Lamb; David Joseph; Keen-Hun Tai; Shawn Malone; Charles Ludgate; Allison Steigler; Philip W Kantoff Journal: J Clin Oncol Date: 2007-06-10 Impact factor: 44.544